Literature DB >> 23770851

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.

T Sun1, X Wang1, H H He2, C J Sweeney1, S X Liu3, M Brown1, S Balk4, G-Sm Lee1, P W Kantoff1.   

Abstract

Hormone-sensitive prostate cancer typically progresses to castration resistant prostate cancer (CRPC) after the androgen deprivation therapy. We investigated the impact of microRNAs (miRs) in the transition of prostate cancer to CRPC. MiR-221/-222 was highly expressed in bone metastatic CRPC tumor specimens. We previously demonstrated that transient overexpression of miR-221/-222 in LNCaP promoted the development of the CRPC phenotype. In current study, we show that stably overexpressing miR-221 confers androgen independent (AI) cell growth in LNCaP by rescuing LNCaP cells from growth arrest at G1 phase due to the lack of androgen. Overexpressing of miR-221 in LNCaP reduced the transcription of a subgroup of androgen-responsive genes without affecting the androgen receptor (AR) or AR-androgen integrity. By performing systematic biochemical and bioinformatical analyses, we identified two miR-221 targets, HECTD2 and RAB1A, which could mediate the development of CRPC phenotype in multiple prostate cancer cell lines. Downregulation of HECTD2 significantly affected the androgen-induced and AR-mediated transcription, and downregulation of HECTD2 or RAB1A enhances AI cell growth. As a result of the elevated expression of miR-221, expression of many cell cycle genes was altered and pathways promoting epithelial to mesenchymal transition/tumor metastasis were activated. We hypothesize that a major biological consequence of upregulation of miR-221 is reprogramming of AR signaling, which in turn may mediate the transition to the CRPC phenotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770851      PMCID: PMC3883998          DOI: 10.1038/onc.2013.230

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

Review 1.  TM4 microarray software suite.

Authors:  Alexander I Saeed; Nirmal K Bhagabati; John C Braisted; Wei Liang; Vasily Sharov; Eleanor A Howe; Jianwei Li; Mathangi Thiagarajan; Joseph A White; John Quackenbush
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.

Authors:  Jindan Yu; Qi Cao; Rohit Mehra; Bharathi Laxman; Jianjun Yu; Scott A Tomlins; Chad J Creighton; Saravana M Dhanasekaran; Ronglai Shen; Guoan Chen; David S Morris; Victor E Marquez; Rajal B Shah; Debashis Ghosh; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

3.  MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.

Authors:  Tyler E Miller; Kalpana Ghoshal; Bhuvaneswari Ramaswamy; Satavisha Roy; Jharna Datta; Charles L Shapiro; Samson Jacob; Sarmila Majumder
Journal:  J Biol Chem       Date:  2008-08-15       Impact factor: 5.157

4.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.

Authors:  F Fornari; L Gramantieri; M Ferracin; A Veronese; S Sabbioni; G A Calin; G L Grazi; C Giovannini; C M Croce; L Bolondi; M Negrini
Journal:  Oncogene       Date:  2008-06-02       Impact factor: 9.867

5.  A novel monoclonal antibody against human Argonaute proteins reveals unexpected characteristics of miRNAs in human blood cells.

Authors:  Peter T Nelson; Mariangels De Planell-Saguer; Stella Lamprinaki; Marianthi Kiriakidou; Paul Zhang; Una O'Doherty; Zissimos Mourelatos
Journal:  RNA       Date:  2007-08-24       Impact factor: 4.942

6.  MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.

Authors:  Jian-Jun Zhao; Jianhong Lin; Hua Yang; William Kong; Lili He; Xu Ma; Domenico Coppola; Jin Q Cheng
Journal:  J Biol Chem       Date:  2008-09-12       Impact factor: 5.157

Review 7.  The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

Authors:  Francesca Bernassola; Michael Karin; Aaron Ciechanover; Gerry Melino
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

Review 8.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

Review 9.  Mechanisms mediating androgen receptor reactivation after castration.

Authors:  Xin Yuan; Steven P Balk
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

10.  Analysis of GTPase-activating proteins: Rab1 and Rab43 are key Rabs required to maintain a functional Golgi complex in human cells.

Authors:  Alexander K Haas; Shin-ichiro Yoshimura; David J Stephens; Christian Preisinger; Evelyn Fuchs; Francis A Barr
Journal:  J Cell Sci       Date:  2007-08-07       Impact factor: 5.285

View more
  55 in total

1.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

2.  The proinflammatory role of HECTD2 in innate immunity and experimental lung injury.

Authors:  Tiffany A Coon; Alison C McKelvey; Travis Lear; Shristi Rajbhandari; Sarah R Dunn; William Connelly; Joe Y Zhao; SeungHye Han; Yuan Liu; Nathaniel M Weathington; Bryan J McVerry; Yingze Zhang; Bill B Chen
Journal:  Sci Transl Med       Date:  2015-07-08       Impact factor: 17.956

3.  Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.

Authors:  Laura Foj; Xavier Filella
Journal:  Pathol Oncol Res       Date:  2018-10-26       Impact factor: 3.201

4.  miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells.

Authors:  Min Jin; Tao Zhang; Can Liu; Mark A Badeaux; Bigang Liu; Ruifang Liu; Collene Jeter; Xin Chen; Alexander V Vlassov; Dean G Tang
Journal:  Cancer Res       Date:  2014-06-05       Impact factor: 12.701

5.  Hypoxia-mediated miR-212-3p downregulation enhances progression of intrahepatic cholangiocarcinoma through upregulation of Rab1a.

Authors:  Panzhang Hou; Yi Kang; Jianchao Luo
Journal:  Cancer Biol Ther       Date:  2018-05-14       Impact factor: 4.742

Review 6.  Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.

Authors:  Nicholas H Farina; Areg Zingiryan; Michael A Vrolijk; Scott D Perrapato; Steven Ades; Gary S Stein; Jane B Lian; Christopher C Landry
Journal:  J Cell Physiol       Date:  2018-04-16       Impact factor: 6.384

Review 7.  MicroRNAs in the control of metastatic bone disease.

Authors:  Gillian Browne; Hanna Taipaleenmäki; Gary S Stein; Janet L Stein; Jane B Lian
Journal:  Trends Endocrinol Metab       Date:  2014-05-05       Impact factor: 12.015

8.  miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.

Authors:  Chris Zhiyi Zhang; Yun Cao; Jia Fu; Jing-Ping Yun; Mei-Fang Zhang
Journal:  Mol Oncol       Date:  2016-09-20       Impact factor: 6.603

Review 9.  Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.

Authors:  Seong Lin Teoh; Srijit Das
Journal:  Tumour Biol       Date:  2016-09-14

Review 10.  MicroRNAs and drug resistance in prostate cancers.

Authors:  Feng Li; Ram I Mahato
Journal:  Mol Pharm       Date:  2014-04-29       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.